George Pell is the Principal and Chief Strategy Officer of Thirty-Six, an innovation studio bringing a series of ventures to life for advancing neuroscience, medical intelligence, and human potential. George brings over 20 years from this space, where emerging technologies are first crafted and brought to life, including several which have helped shape the landscape of AI for the life sciences, such as discovery, augmented intelligence, and other cognitive technologies. He has made a multi-billion dollar impact in a range of innovation, strategy, and transformation roles for some of the world’s largest companies in the most high stakes of circumstances. George has invested his most recent 14 years in the life sciences space, where he brings a multidiscipline of advanced biology together with discovery and intelligence technologies, for next-gen applications in neuroscience and precision medicine.
Dr. Girish Srinivasan, Co-Founder & CTO of PhenoMx Inc., is an accomplished healthcare professional and entrepreneur with 20+ years of experience in building medical technology solutions. He has an MS in computer science (Artificial Intelligence) and a Ph.D. in biomedical engineering (Medical Imaging & Data Analytics). He currently also serves on the advisory board of niche organizations to integrate and deploy AI solutions for diagnostic automation. In the past, he has led R&D, product strategy, clinical research, and marketing teams at Toshiba Medical, GE Healthcare, and Samsung Healthcare. He has deep experience in medical imaging and has delivered various clinical applications for MRI, CT, Ultrasound, and digital X-rays. Solutions, he has been instrumental in creating, have been deployed across global institutions. He is currently leading efforts on radiomocis and phenotyping for precision healthcare.
George Pell is the Principal and Chief Strategy Officer of Thirty-Six, an innovation studio bringing a series of ventures to life for advancing neuroscience, medical intelligence, and human potential. George brings over 20 years from this space, where emerging technologies are first crafted and brought to life, including several which have helped shape the landscape of AI for the life sciences, such as discovery, augmented intelligence, and other cognitive technologies. He has made a multi-billion dollar impact in a range of innovation, strategy, and transformation roles for some of the world’s largest companies in the most high stakes of circumstances. George has invested his most recent 14 years in the life sciences space, where he brings a multidiscipline of advanced biology together with discovery and intelligence technologies, for next-gen applications in neuroscience and precision medicine.
Dr. Girish Srinivasan, Co-Founder & CTO of PhenoMx Inc., is an accomplished healthcare professional and entrepreneur with 20+ years of experience in building medical technology solutions. He has an MS in computer science (Artificial Intelligence) and a Ph.D. in biomedical engineering (Medical Imaging & Data Analytics). He currently also serves on the advisory board of niche organizations to integrate and deploy AI solutions for diagnostic automation. In the past, he has led R&D, product strategy, clinical research, and marketing teams at Toshiba Medical, GE Healthcare, and Samsung Healthcare. He has deep experience in medical imaging and has delivered various clinical applications for MRI, CT, Ultrasound, and digital X-rays. Solutions, he has been instrumental in creating, have been deployed across global institutions. He is currently leading efforts on radiomocis and phenotyping for precision healthcare.
Xiao Li is an assistant professor at Case Western Reserve University. She is highly motived to use machine learning techniques to integrate genomic, clinic and digital data to monitor changes during healthy and diseased states and improve the ability to prevent, diagnose, and treat diseases. During her Ph.D. study, she received both computational and biological training under the supervision of Drs. Quaid Morris and Howard Lipshitz at the University of Toronto, where her research focused on the binding and function of RNA binding proteins. During the postdoctoral training, she led the wearable team in Michael Snyder lab and performed the groundwork for the proposed research by investigating the impact of wearable devices in health management. She developed change-of-heart algorithm to use wearable-measured heart rate for early warning of infectious diseases. This work has generated a lot of excitement (>88K views and reported by ~50 news organizations including WIRED, TIME, etc).
Mark H. Michalski MD is a physician with 15+ years of experience at the intersection of medical technology, data science, devices, and clinical medicine. He has most recently served as founding Executive Director of the Center for Clinical Data Science (CCDS) at Massachusetts General Hospital and Brigham and Women’s Hospital, and as faculty at Harvard Medical School.
A unique, product-focused organization empowered to leverage the data resources of both hospitals, and backed by multiple corporate partners (NVidia, GE, Nuance, FujiFilm), the CCDS has co-developed products for nearly every clinical specialty, as well as non-clinical solutions in operations and population risk management. Before this role, Dr. Michalski served as president and CMO of Butterfly Network and was founding CMO and commercial lead for Hyperfine Research. He has conducted research focused on machine learning, medical 3-D printing, and molecular diagnostics, has published in journals such as JAMA, PLOS, and PNAS, and has given over 80 invited talks. Previous to these roles, Dr. Michalski worked in various technology and strategy groups at Genentech and Google. He completed his diagnostic radiology residency as a Holman fellow at Yale, his medical degree at Stanford, and a BS in Cybernetics at UCLA.
Dr. Prasun Mishra is an investor, co-founder, advisor, and board member of a few US-based corporations; he has numerous publications/patents, several drugs in clinical trials, and has over 40 prestigious awards honors to his credit. He is the founder and CEO of Agility Pharmaceuticals, a technology-driven pharmaceutical company committed to revolutionizing drug discovery & development. Dr. Mishra is also the founding president and chair of the American Association for Precision Medicine and the AAPM Innovation Center, where he is leading research efforts focused on preventing & curing chronic diseases, treating the sick, and providing knowledge/tools to individuals to live longer, healthier lives.
He is a serial entrepreneur who founded his first company after graduating high school and his second company during his Ph.D. Since then, he has accumulated a wealth of experience by building, investing, and advising numerous other companies. He is also a General Partner in the Global Health Impact Network and Fund, a healthcare-focused investment fund based in Silicon Valley, CA. He is also a founding chair of WISE: World Investors and Entrepreneurs Society, an investment collective with a global investment footprint. He is a founding investor and advisor to Barcelona Ventures and an advisor to a $100M private equity fund.
He served as a Scientist and Principal Investigator at the pharma giant Genentech, Roche. Where he participated in several drug discovery project teams; moreover, his passion for drug development and precision medicine has led to the identification of new drug targets, biomarkers, companion diagnostics, and several drugs/ combinations in the clinic.
A mathematician with over 10 years expertise in actively managing innovation in life science companies, Olga Kubassova, PhD, is a healthcare innovator and biotech investor with passion for improving people’s health. She has co-authored over 60 publications, books and book chapters, has become a scientific adviser to the UK government and EU funding bodies. She is a four-time winner of national and international "Entrepreneur of the Year" awards. Olga’s ambition is to bring truly disruptive technologies, artificial intelligence and best of machine learning to clinical practice and research, while expanding IAG's footprint and partnerships.
Daniel Kraft is a Stanford and Harvard trained physician-scientist, inventor, entrepreneur, and innovator. With over 25 years of experience in clinical practice, biomedical research and healthcare innovation, Kraft has served as Faculty Chair for Medicine at Singularity University since its inception in 2008, and is the Founder and Chair of Exponential Medicine, a program that explores convergent, rapidly developing technologies and their potential in biomedicine and healthcare.
Following undergraduate degrees from Brown University and medical school at Stanford, Daniel was Board Certified in both Internal Medicine & Pediatrics after completing a Harvard residency at the Massachusetts General Hospital & Boston Children's Hospital, and fellowships in hematology, oncology and bone marrow transplantation at Stanford.
He has multiple scientific publications and medical device, immunology and stem cell related patents through faculty positions with Stanford University School of Medicine and as clinical faculty for the pediatric bone marrow transplantation service at University of California San Francisco.
Dr. Matthew Brown is a Professor of Radiological Sciences at UCLA. He is the director of the Center for Computer Vision and Imaging Biomarkers (CVIB) at UCLA and a co-founder of MedQIA an imaging contract research organization. His scientific interests focus on computer vision and computer-aided diagnosis in medical imaging. Current imaging biomarker applications include multi-modality tumor detection and feature analysis, and image-based classification of diffuse lung disease.
David is Co-Founder/CEO of Colby Pharmaceutical Company, San Rafael, California. Colby clinically develops anti-inflammatory small molecule pharmaceutical drugs, immunotherapeutic and preventative vaccines with companion diagnostics in elderly, adult, adolescent patients for acute/chronic inflammation in immuno-oncology/-virology, including product candidates for acute respiratory distress syndrome, allergy and infectious disease. David was trained in molecular-virology, -oncology, -immunology at Dartmouth College, Baylor College of Medicine and UWisconsin-Madison Medical School. At UC-Berkeley, UC-San Francisco, Stanford Research Institute and Pangene Corporation, David led cross-functional-teams which developed recombinase-mediated-isothermal-gene-amplification and gene-family-cloning. At SRI, David teamed in completing acquisition of Sarnoff Corporation as a profitable SRI-subsidiary, led therapeutics/companion diagnostics, and commercialized nucleic acid-/antigen-/antibody-/drug-multiplex-diagnostic systems using Sarnoff-infrared-activated-UpConvertingPhosphor-ultrasensitive-visually-detectable-reporters for laser-diode-UCP-signal amplification with hand-held-diagnostics. At Colby, David sold three oncology drugs in early-clinical/late-pre-clinical development, merged Colby with Othera Pharmaceuticals’ clinical anti-inflammatory-nitroxide drugs, developed intralymphatic-, intradermal- and orally-administered vaccines with companion diagnostics (i.e., HPV-induced-HNSCC) and is continuing development of infectious disease vaccines.
Mike received advanced training in medicinal-organic chemistry and nano-biotechnology at Loughborough-/Nottingham-/Oxford-Universities. He subsequently held positions of increasing responsibility at Amersham/GE Healthcare, Celltech, Medisense/Abbott, Integrated Genetics, IGEN and Microgenics. Mike Powell is an internationally recognized innovator of commercial diagnostic cancer-- and virus--Protein-Antigen-/DNA-/RNA-/Cell-Diagnostic Systems and Companion Diagnostic Instrumentation. This includes, Mike Powell’s discovery and commercialization of XenoNucleic Acid (XNA) target-PCR-amplification or signal-Branched-amplification diagnostic reactions for Clinical-Oncology & -Virology or XNA-Allele-Specific- and XNA-NGS (Next Generation Sequencing) DiaCarta diagnostics. Previous to DiaCarta, Mike was CSO, Nanopoint [microfabricated (MEMS) slide-based imaging-system/reagents for gene mapping/cell analyses]; founded Odyssey Thera (gene-target-validation/drug-discovery); pioneered commercial applications of Catalytic Antibodies & ElectroChemiLuminescence for Roche-Diagnostics automated-in-vitro-diagnostic-immunoassays at IGEN; and was new technology Director at: Microgenics/Boehringer-Mannheim/Roche-Diagnostics.
Momo Vuyisich is a co-founder and Chief Science Officer at Viome, a data-driven precision nutrition company. Momo provides scientific leadership at Viome and his vision is to revolutionize healthcare from "symptoms management" to a true preventative medicine. He leads product development, clinical test implementation, and comprehensive clinical research portfolio. Momo is also an Adjunct Professor at the University of New Mexico and New Mexico Tech. Before co-founding Viome in 2016, Momo spent 12 years at Los Alamos National Laboratory, where he led the Applied Genomics team, which developed the core technology used by Viome today. Momo received his PhD in Biochemistry from the University of Utah, and BS in Microbiology from the University of Texas at El Paso.
